NDASUBCUTANEOUSPOWDER
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Clinical Trials (5)
A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Started Feb 2026
160 enrolled
Achondroplasia
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Started Jul 2025
60 enrolled
Hypochondroplasia
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Started Jun 2025
140 enrolled
Hypochondroplasia
A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
Started Nov 2024
54 enrolled
Short Stature Homeobox- Containing Gene SHOX DeficiencyNoonan SyndromeTurner Syndrome
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
Started Oct 2024
100 enrolled
Idiopathic Short Stature
Loss of Exclusivity
LOE Date
Jul 11, 2042
199 months away
Patent Expiry
Jul 11, 2042
Exclusivity Expiry
Oct 20, 2030